Lexicon Pharmaceuticals, Inc. Q3 2025 Earnings Recap

LXRX Q3 2025 November 6, 2025

Get alerts when LXRX reports next quarter

Lexicon Pharmaceuticals reported strong progress in advancing its R&D pipeline during Q3 2025, with significant milestones reached across key therapeutic programs, despite ongoing challenges in the regulatory landscape.

Earnings Per Share Beat

$-0.04 vs $-0.07 est.

+42.9% surprise

Revenue Beat

14182000 vs 3141590 est.

+351.4% surprise

Market Reaction

1-Day +3.62%

5-Day +13.04%

30-Day -1.45%

See LXRX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Achieved Phase III readiness for pilavapadin, targeting diabetic peripheral neuropathic pain, and ongoing discussions with the FDA for next steps.
Completed IND-enabling studies for LX9851, entering a partnership with Novo Nordisk that may yield up to $30 million in milestone payments.
Active enrollment in the Phase III SONATA study for sotagliflozin, addressing both obstructive and non-obstructive hypertrophic cardiomyopathy subtypes.
Implemented an innovative virtual sales system aimed at transforming INPEFA into a profitable revenue stream by 2026.
Engaged in proactive discussions with the FDA regarding Zynquista, providing additional supporting data to address previous regulatory concerns.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit LXRX on AllInvestView.